Biotech entity
Every one of those 1 sits in a single category, pharma. TELA Bio is most often covered alongside Intrusion Inc., which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. TELA Bio is most often covered alongside Intrusion Inc., which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Biotech story that mention TELA Bio, all published on March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TELA Bio. Shared-story counts are live from our verified record — not editorial picks.
TELA Bio reported its fourth-quarter and full-year 2025 financial results, highlighting the steady adoption of its OviTex reinforced tissue matrices. The report comes amid a busy earnings cycle that also saw leadership changes at Reed's Inc. and financial updates from Intrusion Inc.
TELA Bio is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
